Papulopustular Rosacea - Pipeline Insight, 2024

This “Papulopustular Rosacea- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Papulopustular Rosacea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Papulopustular Rosacea: Understanding

Papulopustular Rosacea: Overview

Papulopustular rosacea, sometimes referred to as inflammatory rosacea, is a type of skin condition that may sometimes be mistaken for acne. Papulopustular rosacea often begins as pus-filled or red bumps that form close together on skin. Skin may also feel hot to the touch or itchy along with frequent breakouts. Those with lighter skin may see the rosy-red flush this condition is named for; while those with darker skin may find their flush tends toward yellow or dusty brown. Sometimes referred to as inflammatory rosacea, papulopustular rosacea is always associated with bumps or texture (sometimes referred to as plaque) of some sort. The cause of all types of rosacea are not entirely understood, though it may be due to a combination of genetics and environmental triggers. Some of the most common rosacea triggers, according to the AAD, are: sunlight and high temperatures, wind and low temperatures, high stress and exercise, some medications and supplements, spicy foods and hot beverages, food that contains the compound cinnamaldehyde, alcohol, hairspray or other hair products,the presence of a skin mite called demodex and the bacterium it carries, Bacillus oleronius. Papulopustular rosacea is associated with “whitehead” pustules, which are pus-filled blemishes, and red, swollen bumps. These typically appear on the cheeks, chin, and forehead and are frequently misidentified as acne. Facial redness and flushing may appear, as well. Severe papulopustular rosacea can cause upwards of 40 blemishes that can take a long time to go away. Blemishes may also appear on the scalp, neck, or chest. There is not currently a cure for rosacea, though symptoms can be managed. While there is no cure for this type of rosacea, certain lifestyle tweaks - such as avoiding very spicy foods and too much time in the sun - may make the chronic skin condition more manageable.

Papulopustular Rosacea- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Papulopustular Rosacea pipeline landscape is provided which includes the disease overview and Papulopustular Rosacea treatment guidelines. The assessment part of the report embraces, in depth Papulopustular Rosacea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Papulopustular Rosacea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Papulopustular Rosacea R&D. The therapies under development are focused on novel approaches to treat/improve Papulopustular Rosacea.

Papulopustular Rosacea Emerging Drugs Chapters

This segment of the Papulopustular Rosacea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Papulopustular Rosacea Emerging Drugs

DMT310: Dermata TherapeuticsDMT310 is the lead product candidate, developed from Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. After processing, the sponge powder contains precisely sized and shaped silica spicules that upon application may help exfoliate the skin, promote collagen production, open closed comedones (creating an aerobic environment to help kill C. acne bacteria) and create microchannels to facilitate penetration of the sponge’s naturally occurring chemical compounds. These chemical compounds have been shown, in-vitro, to have both antimicrobial and anti-inflammatory properties, which is believed to play a significant role in the treatment of inflammatory skin diseases, such as acne.

BPX-04: Timber PharmaceuticalsBPX-04 (minocycline), is a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea. The product has demonstrated safety and efficacy in a randomized, double-blind, vehicle-controlled Phase 2b clinical trial which enrolled 206 subjects with moderate-to-severe papulopustular rosacea. In addition to meeting the primary and secondary endpoints of the trial, BPX-04 demonstrated a statistically significant reduction in the number of facial inflammatory lesions at all-time points (weeks 4, 8 and 12).

Papulopustular Rosacea: Therapeutic Assessment

This segment of the report provides insights about the different Papulopustular Rosacea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Papulopustular Rosacea

There are approx. 20+ key companies which are developing the therapies for Papulopustular Rosacea. The companies which have their Papulopustular Rosacea drug candidates in the most advanced stage, i.e. Phase II, Timber Pharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Papulopustular Rosacea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Papulopustular Rosacea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Papulopustular Rosacea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Papulopustular Rosacea drugs.

Papulopustular Rosacea Report Insights

• Papulopustular Rosacea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Papulopustular Rosacea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Papulopustular Rosacea drugs?
• How many Papulopustular Rosacea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Papulopustular Rosacea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Papulopustular Rosacea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Papulopustular Rosacea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Timber Pharmaceuticals
• Dermata Therapeutics
• CAGE Bio
• Promius Pharma
• Alfasigma
• BioMimetix

Key Products

• DMT310
• BPX-04
• CGB-400
• DFD-29
• Rifaximin
• BMX-010

This product will be delivered within 1-3 business days.